Overview

Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation

Status:
Not yet recruiting
Trial end date:
2030-08-20
Target enrollment:
Participant gender:
Summary
Aim to compare chemotherapy alone or chemoradiotherapy for post-operative endometrial cancer (stage I-IVA) with p53 mutation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Fudan University
Treatments:
Carboplatin
Paclitaxel